Science 37 has been recognized with Frost & Sullivan’s 2024 Company of the Year Award in the global decentralized clinical trials industry, standing out for its innovation, quality, and customer impact. Download the report here: https://lnkd.in/gA-k6QfR #Science37Awards #FrostAwards #clinicalresearch #clinicaltrials #decentralizedtrials #healthcare
Science 37
Research Services
Morrisville, North Carolina 26,034 followers
Access More Patients. Enroll Faster.
About us
Science 37’s mission is to accelerate clinical research by enabling universal trial access for patients. Through our solutions; the Metasite™ and Patient Recruitment, we accelerate enrollment by expanding the reach of clinical trials to patients beyond the traditional site and rigorously qualifying patients prior to referring them to a traditional site. Our solutions are powered by a proprietary technology stack with in-house medical and operational experts that enhance quality through standardized workflows and best-in-class study orchestration.
- Website
-
www.science37.com
External link for Science 37
- Industry
- Research Services
- Company size
- 501-1,000 employees
- Headquarters
- Morrisville, North Carolina
- Type
- Public Company
- Founded
- 2014
- Specialties
- Patient Recruitment, Patient Qualification, Clinical Trial Enrollment, Clinical Trial Access, Site Conduct, Virtual Site, Hybrid Clinical Trials, Remote Clinical Trials, Decentralized Clinical Trials, Clinical Trial Technology, and Real-World Evidence
Locations
-
Primary
Get directions
Research Triangle Park
Morrisville, North Carolina, US
Employees at Science 37
Updates
-
Science 37 will be at SCOPE Europe! Ways to connect with our team at the event: 🤝 Speak with Mark Arrowsmith & Maja Mijajlović at booth #4 to learn more about our clinical trial solutions for accelerating recruitment and enrollment. 🎤 Join Alina (Dawson) Wherry, Director of Clinical Operations, for a presentation on “Unlocking the Power of DCT: Navigating Trial Design Considerations in Modern Models” on Tuesday, October 29 @ 4:07 PM. Interested in scheduling a time to connect with one of our team members? Send us a LinkedIn message. #SCOPEEurope #SCOPEEU #SCOPESummit #clinicalresearch #clinicaltrials #clinicalstudies
-
-
🏊♂️🚴♂️🏃♂️ Shoutout to our Senior Director of Strategic Solutions, Jeffrey Golden, for his incredible achievement at IRONMAN Maryland last month! 🏅 Jeff took on the grueling challenge of a 2.4-mile swim, a 112-mile bike ride, and a full 26.2-mile marathon – all while proudly representing Science 37 in his race gear. 🙌 Despite the bike and run courses being partially flooded, Jeff powered through and showed what true determination looks like. Not only does he go the distance for his team and our mission, but he also goes the extra mile (literally) to break new ground and inspire. His commitment, whether it’s in the office or out on the course, is a true reflection of our drive to break barriers in clinical research. Swipe through to see Jeff in action! #Science37Spotlight #IRONMAN
-
-
Science 37 is proud to partner with Vedanta Biosciences, Inc. on their pivotal Phase 3 RESTORATiVE303 study. Through our decentralized Metasite™ model, we're bringing the trial directly to patients' homes, making participation easier and more accessible for those with recurrent C. diff. #clinicalresearch #clinicaltrials #clinicalstudies
Due to the nature of C. diff infections, particularly the high recurrence rate following standard treatments, participating in a clinical trial may be an option for sufferers who don’t respond to antibiotics. Some clinical trials focus on developing vaccines and other preventatives. Vedanta Biosciences, Inc. is a late-stage clinical biotechnology company developing first-in-class oral therapies for the treatment of serious gastrointestinal diseases. VE303 is an investigational treatment for patients with recurrent C. difficile infections (CDI). VE303 is a preparation of eight different types of bacteria grown in clean conditions, dried, powdered and put into capsules to be administered orally. RESTORATiVE303 is their Phase III clinical research study that is exploring the investigational drug to restore the microbiome in people with recurrent C. diff. There are study sites across the US and Canada. Find a study site and read more about the study here https://buff.ly/4eehh2r Vedanta has teamed up with Science37 to provide a site-less, decentralized approach. This means the study can be done remotely and the product comes to you, in your home. This allows applicants who are not near a study site or unable to travel to participate and receive treatment. You can sign up for the decentralized study here https://buff.ly/3ZChesC
-
-
Less than 10% of the U.S. population has access to participate in clinical trials—a staggering gap in healthcare opportunities. Geographical barriers, logistical hurdles, and a lack of awareness are major factors behind this low participation rate. Many potential participants live far from research sites, struggle with transportation, or can't take time off work, limiting their ability to contribute to research. At Science 37, we recognize these obstacles hinder medical progress and affect patient care. That's why our mission is to expand access for all. Contact us today to see how we can make your trial more convenient and accessible for participants. https://lnkd.in/e2v6DfFf
-
We are pleased to welcome Jeff V. to Science 37 as our new Senior Sales Operations Manager! With more than a decade of experience in driving revenue, expanding market reach, and leading high-performing teams across diverse markets, Jeff is a fantastic addition to our growing team. Jeff is already making an impact by establishing and managing strategic systems, process improvements, and advanced data analytics to enhance operational effectiveness. We look forward to achieving new milestones together.
-
-
We’re excited to see the FDA finalize the guidance on “Conducting Clinical Trials with Decentralized Elements.” This aligns with our mission at Science 37 to accelerate clinical research by enabling universal trial access for patients, ultimately making clinical trials convenient and available to everyone. During our recent FDA inspection, we saw the agency's genuine openness to adopt new approaches in trial execution, particularly around the use of technology to support protocol execution and improve participant engagement, enrollment, and retention, resulting in stronger outcomes and data. We see this final guidance as real support from the regulators for the Science 37 model. To learn more about our approach, please visit www.science37.com. Irena Lambridis
FDA issued a final guidance, “Conducting Clinical Trials with Decentralized Elements,” providing recommendations for sponsors, investigators, and other interested parties regarding the implementation of decentralized elements in clinical trials: https://lnkd.in/exDQdykh Decentralized elements allow trial-related activities to occur remotely at locations convenient for trial participants. By enabling remote participation, decentralized clinical trials may: ☑️ Enhance convenience for trial participants ☑️ Reduce the burden on caregivers ☑️ Expand access to more diverse patient populations ☑️ Improve trial efficiencies ☑️ Facilitate research on rare diseases and diseases affecting populations with limited mobility This guidance is a part of a multifaceted FDA effort to help modernize clinical trial design and conduct to improve efficiency and reduce burden on participants and on those conducting the trial.
-
Welcome to a "Day in the Life" of a Science 37 mobile Clinical Research Nurse! 🚙🏠 💼🩺💉 Tyler Oliver gives us a behind-the-scenes look into how our Virtual Site solution allows for home-based clinical trial participation by bringing study visits directly to patients' doorsteps. #Science37Spotlight #clinicalresearch #clinicaltrials #clinicalstudies #healthcare #nursing
-
Stefan Jovanović and Mark Arrowsmith from Science 37 are attending #OCTNordics over the next two days. Don’t miss the opportunity to connect with them in person! 🤝 Reach out directly to schedule a time to meet and explore how we can collaborate.
Are you attending OCT Nordics in Copenhagen next week? 🇩🇰 If so, let's catch up - my colleague Mark Arrowsmith and I would be happy to share how Science 37 can accelerate enrollment for your next US clinical study! 📈
-
-
We're excited for this unique discussion happening later today at the #SCRS2024 Global Site Solutions Summit. If you’re onsite, don’t miss out—join us for valuable insights!
🎤 Science 37's Dr. Debra Weinstein will participate in the Candid Investigator Insights Roundtable at the #SCRS Global Site Solutions Summit on Saturday, Sept 28 @ 4:00 - 5:00 PM. During this special session, investigators will engage in open, transparent discussions, share valuable insights, and address site-level challenges head-on. It’s a unique opportunity to collaborate and drive meaningful solutions in clinical research. We can't wait! Society for Clinical Research Sites (SCRS) #clinicalresearch #clinicaltrials #clinicalstudies
-